Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan clues may predict who benefits from epilepsy procedure

NCT ID NCT07399327

Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with drug-resistant focal epilepsy who are already scheduled for a brain-mapping procedure called SEEG. At the end of that procedure, doctors sometimes use heat (thermocoagulation) to destroy small areas of brain tissue that cause seizures. The study will use advanced MRI scans and blood tests to see if changes in the brain's barrier and electrical signals can predict who will have fewer seizures after the heat treatment. The goal is to find better ways to choose the right targets for this procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SEEG-guided radiofrequency thermocoagulation (RFTC)
What this could lead to
If successful, this could help doctors better select which brain targets to treat with thermocoagulation, improving seizure control for people with drug-resistant epilepsy.
What could go wrong
This is an early observational study with only 45 participants, so results may not apply to everyone. It focuses on understanding mechanisms, not proving a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient, parents or legal representative who have given their written informed consent, * Adult or pediatric patient ≥ 12 years old suffering from drug-resistant focal epilepsy, * Standardized pre-surgical assessment including medical history, scalp video-EEG and 3T MRI, * Patients in whom a SEEG exploration for pre-surgical evaluation has been indicated, * Patient able to understand, speak and write in French, * Patient able to follow study's procedure, * Patient beneficiary or affiliated to a health insurance plan. Exclusion Criteria: * Epilepsy surgery performed without the requirement of SEEG, * Contraindication to 3T or 7T brain MRI (patient with a cardiac pacemaker, metallic foreign bodies, non-removable implanted electronic medical devices, claustrophobia, inability to remain in supine position, patient havingwith Vagus Nerve Stimulation (VNS) or Deep Brain Sstimulation (DBS), intrauterine devices or tattoos in the imaging area less than 6 weeks old at the time of the 3T/7T brain MRI), * Contraindication to gadolinium-based MRI contrast agent (history of allergic or anaphylactic reaction to gadolinium, hypersensitivity to gadoteric acid, meglumine, or any drug containing gadolinium, severe renal failure (glomerular filtration rate, GFR, below 30 ml/min/1.73 m2), patients on dialysis or with a history of kidney disease, such as renal transplantation, a single kidney, or renal malignancy), * Person protected by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent), * Patient in exclusion period of another study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug resistant epilepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug resistant epilepsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux Marseille

    RECRUITING

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.